MRVI Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings has seen its share price swing sharply in recent years, which raises a straightforward question for anyone looking at the stock today. Is the current US$7.65 price supported by the cash flows the business can generate over time, based on a Discounted Cash Flow (DCF) view of its intrinsic value? The stock has delivered a 171.3% return over the past year, which puts real pressure on the question of whether that move is fully backed by the cash the business is...

Maravai LifeSciences Holdings (MRVI) has been drawing attention after recent share price swings, with the stock closing at US$7.37 on 24 September 2026. Investors are weighing mixed return patterns across different holding periods. Recent trading in Maravai LifeSciences Holdings has been choppy, with a 7-day share price return of 7.75% but a 30-day move that is down 12.57%, while the 90-day gain of 20.42% and year to date share price return of 116.76% signal momentum that has cooled recently...

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a

Revenue grew 8.5% to $51.4 million as mRNA discovery demand surged.

Moby summary of Maravai LifeSciences Holdings, Inc.'s Q2 2026 earnings call

Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast. Revenue for the quarter was $51.4 million, up 9% from the prior-year period. CE

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?